RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
HitGen, a Chengdu small molecule discovery company, has been approved for a $97 million IPO on Shanghai’s new Science and Technology Innovation Board. HitGen has built a DNA-encoded library that contains nearly 400 billion novel, diverse, drug-like small molecule and macrocyclic compounds. The company is a partnering wonder, having formed more than 60 drug discovery partnerships with a collection of well-known China and global pharmas, including big pharma companies. It has also developed its own portfolio of 20 candidates for various cancer, cardiovascular, inflammatory and metabolic indications.
Source: China Biotoday